Circulating tumour DNA as a noninvasive biomarker in melanoma

黑色素瘤治疗方案的不断扩大使人们关注需要改进的方法，以准确监测治疗反应并指导治疗决定。许多癌症向血液中排放少量的DNA(CtDNA)，ctDNA水平的变化有可能被用作癌症治疗反应的特定标记物。该项目将评估ctDNA是否可以作为一种形式的液体活组织检查来指导黑色素瘤患者的治疗决定。

The expanding repertoire of treatment options in melanoma is bringing into focus the need for improved ways to accurately monitor treatment responses and guide treatment decisions. Many cancers shed small amounts of DNA (ctDNA) into the bloodstream and changes in ctDNA levels have potential to be used as specific markers of response to cancer therapy. This project will evaluate if ctDNA can be used as a form of ‘liquid biopsy’ to guide treatment decisions in patients with melanoma.